1

## 1 Pharmacogenetics of efavirenz exposure in cervicovaginal fluid during pregnancy and postpartum

- Oluwasegun Eniayewu<sup>1</sup>, Uche Azuka<sup>2</sup>, Jonah Ogah<sup>2</sup>, Ebunoluwa Adejuyigbe<sup>3</sup>, Oluseye Bolaj<sup>4</sup>i, Adeniyi
   Olagunju<sup>5</sup>
- <sup>1</sup>Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of
- 5 Ilorin, Ilorin, Nigeria;
- 6 <sup>2</sup>Federal Medical Centre, Makurdi, Nigeria;
- 7 <sup>3</sup>Department of Paediatrics and Child Health, Faculty of Clinical Sciences, Obafemi Awolowo University, Ile-
- 8 Ife, Nigeria;
- <sup>4</sup> Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife,
   Nigeria.
- <sup>5</sup>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
- 12 \*Correspondence: Dr Adeniyi Olagunju, Sherrington Building, Ashton Street, Liverpool, L69 3GE, United
- 13 Kingdom. Email: olagunju@liverpool.ac.uk. Tel.: +44151 794 0418.
- 14 Running Head: Efavirenz disposition into the FGT
- 15 **Conflict of interest:** None to declare.
- 16 Source of funding: This work was supported in whole, or in part, by the Wellcome Trust International
- 17 Training Fellowship to Adeniyi Olagunju (204776/Z/16/Z). The funder played no role in study design, data
- 18 collection and analysis, decision, preparation of the manuscript or decision to publish.

## 2

## 19 Abstract

## 20 Objectives

Adequate antiretroviral drug distribution into the female genital tract (FGT) could play an important role in reducing the risk of heterosexual and mother-to-child transmission of HIV. In this study, we investigated the combined influence of pregnancy and genetic polymorphisms on efavirenz pharmacokinetics in cervicovaginal fluid (CVF) of women receiving antiretroviral therapy.

#### 25 Methods

A total of 159 women (147 pregnant and 12 postpartum) living with HIV and receiving efavirenz-containing antiretroviral therapy were recruited across two sites in Nigeria (Federal Medical Centre, and Bishop Murray Medical Centre, Makurdi) between 2017-2020. In stage 1, sparse CVF and dried blood spot (DBS) samples were obtained from each participant during pregnancy to assess possible association between drug concentration and *CYP2B6* polymorphisms (516G>T and 983 T>C). In the second stage, participants were stratified into three genotype groups (extensive, intermediate and low metabolisers) and re-enrolled for intensive pharmacokinetic sampling.

## 33 Results

34 In stage 1 (88 CVF, 81 plasma and 73 paired samples), CYP2B6 516G>T was independently associated with both CVF ( $\beta$  = 997 ng/mL (90% CI: 598, 1357), p = 5.7 x 10<sup>-5</sup>) and plasma ( $\beta$  = 1400 ng/mL (90% CI: 1051, 35 1748),  $p = 5.7 \times 10^{-9}$ ) efavirenz concentration during pregnancy. In the second stage (12 pregnant, 12 36 37 postpartum), median (IQR) efavirenz C<sub>min</sub> in CVF during pregnancy versus postpartum was 243 ng/ml (168-38 402) vs 447 ng/ml (159-974), C<sub>max</sub> was 1031 ng/ml (595-1771) vs 1618 ng/ml (675-2695), and AUC<sub>0-24</sub> was 39 16465 ng.h/ml (9356-30417) vs 30715 ng.h/ml (10980-43714). Overall, median CVF-to-plasma AUC ratio 40 was 0.34 during pregnancy and 0.46 postpartum. When patients were stratified using CYP2B6 516G>T, 41 efavirenz median clearance increased by 57.9% during pregnancy compared with postpartum control (p =42 0.232) in patients with the CYP2B6 516GT genotype. The AUC<sub>0-24h</sub> , C<sub>max</sub> and C<sub>min</sub> reduced by 33.8% 43 ((p=0.182), 8.6% (0.175) and 59.5% (0.171) during pregnancy, with values of 20671 ng.h/ml (15993-28712), 44 1550 ng/ml (1090-2090) and 330 ng/ml (250-440), respectively, compared with 31229 ng.h/ml (27660-41873), 1695 ng/ml (1540-3003) and 814 ng/ml (486-981) during postpartum in this genotype. 45

Median efavirenz C<sub>min</sub> in CVF was 1.93 and 3.55 times higher than the PBIC<sub>90</sub> of 126 ng/ml in the pregnant
and postpartum cohorts, respectively.

## 3

## 49 Conclusions

- 50 Efavirenz is well distributed into the CVF, and both pregnancy and polymorphisms in its disposition genes
- 51 affect CVF exposure.
- 52 **Keywords:** Cervicovaginal fluid, Pregnancy, Postpartum, Efavirenz, Pharmacogenetics.

4

## 53 Introduction

54 The understanding of antiretroviral pharmacokinetics in the female genital tract (FGT) is of growing interest 55 in the HIV prevention field because of its importance in designing more effective therapeutic options to 56 reduce serodiscordant and mother-to-child HIV transmission[1]. Although a number of clinical studies that 57 focus on quantifying antiretroviral drugs in the FGT have been reported in the literature[2-6]. ARV 58 characterization in this compartment has not yet been well understood. While pregnancy and 59 polymorphisms have been established to alter ARV plasma exposure[7-10], the knowledge of the effect of 60 these factors on ARV disposition in the FGT is very limited. With evidence of an ongoing risk of viral 61 shedding in FGT, even in patients on suppressive antiretroviral therapy (ART) despite undetectable plasma 62 viremia[11–13], there is a need to further understand antiretroviral dynamics in this compartment to 63 enable the design of effective therapies.

64 MTCT HIV-1 transmission is essentially minimized by suppressing HIV replication and reducing plasma viral 65 load to an undetectable level, particularly at the early stages of pregnancy[14]. Vaginal viral shedding in the 66 instance of suppressed plasma vireamia and in patients newly placed on ART drugs can potentially increase 67 the risk of heterosexual and MTCT HIV transmission [15,16]. As of 2022, an approximated 76.4% (29.8 68 million of the 39 million people living with HIV globally) were reported to be receiving antiretroviral 69 therapies (ART), including at least 8 out of every 10 pregnant women with HIV [17]. Despite this high access 70 to ART, new HIV transmission among children remains substantial, most of it through the perinatal route. 71 Since a substantial proportion of MTCT occurs at the time of delivery via contact with infected female 72 genital fluids [18,19], a significant percentage of these new pediatric HIV infections can be prevented by 73 having a better understanding of ARV disposition in the FGT and factors that could affect FGT drug 74 exposure.

75 The importance of improving the current understanding of ARV pharmacokinetics within and outside the 76 context of pregnancy and pharmacogenetics cannot be overemphasized in the context of designing more 77 effective HIV preventive therapy. However, obtaining robust pharmacokinetic data to achieve this has been 78 constrained by the invasiveness and increased cost associated with sampling genital tissues [20] and the 79 limitations of standardizing existing bioanalytic methods used to quantify ARVs in these compartments [21]. 80 To circumvent these challenges, , cervicovaginal fluids (CVF are used as an acceptable surrogate for vaginal 81 tissue concentrations of ARVs[20]. In our laboratory, we recently validated a minimally invasive LC-MS/MS 82 method to quantify the HIV drug efavirenz in cervicovaginal fluid collected on flock swabs[6], which 83 improved our ability to conduct intensive clinical pharmacokinetic studies with CVF.

5

In this component of the VADICT study, whose protocol was previously published [22], we set out to characterize efavirenz disposition in the FGT and determine the impact of the combined effect of pregnancy and CYP 2B6 Single Nucleotide Polymorphisms (SNPs) on the FGT disposition of the drug.

#### 87 Methods

#### 88 Study sites, participants, and ethics

89 Participants in the VADICT study were recruited from four sites in Benue State, Nigeria (Federal Medical 90 Centre, Makurdi; Bishop Murray Medical Centre, Makurdi; St. Monica's Hospital, Adikpo; and St. Thomas' 91 Hospital, Ihugh) between December 2017 and September 2020. Pregnant or recently postpartum women 92 living with HIV who were at least 18 years old, receiving WHO recommended first-line ART regimen, not 93 taking other medications with known or suspected interaction with ART components, and who had no 94 severe illness were eligible. The study was approved by the National Health Research Ethics Committee, 95 Abuja, Nigeria (approval number: NHREC/01/01/2007-05/06/2017). The study is registered on 96 ClinicalTrials.gov (NCT03284645) and the full protocol has been published elsewhere [22]. Participants for 97 parts of the study reported here were recruited only from Makurdi sites where ultra-low temperature 98 facilities were available.

### 99 Study design

100 The VADICT study was an observational cohort study with a pharmacokinetic component conducted in two 101 stages. In the first stage, we assessed association between established functional single nucleotide 102 polymorphisms (SNPs) in efavirenz disposition gene CYP2B6 (516G>T and 983 T>C) and mid-dose efavirenz 103 concentration in both cervicovaginal fluid and plasma during pregnancy. For stage two, participants were 104 stratified into three metabolizer groups using the independently associated SNP based on the number of 105 variant alleles present: 'slow' (two), 'intermediate' (one), and 'fast' (none). Participants from each group 106 who still satisfied the eligibility criteria at the time the pharmacogenetic data became available were 107 invited for re-enrollment into the intensive pharmacokinetic stage.

### 108 Sample collection and handling

Paired plasma and cervicovaginal fluid samples were collected from each participant at a single recorded timepoint after the last dose. About 1-2mL of plasma was obtained from each participant by centrifugation (4000 rpm) of venous blood samples and transferred into cryovials. Cervicovaginal fluid samples were collected with flocked swabs by a female nurse as described in our paper on this method [23]. In summary, participants laid down on their backs for 5 min before each sample collection to allow pooling of fluid in the

6

back of the vagina. The swab was gently inserted approximately 3 inches into the vagina at first, and inserted further until it touched the back of the posterior fornix. The swab was gently rubbed against the mid-vaginal walls for at least 30 sec, withdrawn and immediately transferred into a cryovial.

117 Participants who were re-enrolled in stage 2 after stratification into slow, intermediate and fast 118 metaboliser underwent intensive pharmacokinetic sampling. CVF and dried blood spot (DBS) samples were 119 collected at six different time points over a single dosing period (pre-dose and at 0.5, 1, 2, 4, 8, and 12 h 120 after dose) following an observed evening dose of ART regimen containing 600 mg efavirenz. Within a few 121 minutes of CVF collection, DBS samples were prepared by spotting drops of whole blood collected on 122 Whatman protein saver cards by finger prick using a 2 mm safety lancet (BD, Oxford, Oxfordshire, UK). DBS 123 cards were dried at ambient temperature (18-25°C) for at least 2 hours, and thereafter packed in ziplock 124 bags with desiccants. Standard operating procedures were prepared for all sample collection processes, 125 and these were performed by trained staff involved in routine care of study participants at each site. All 126 samples were stored at -80°C at the Federal; Medical Centre, Makurdi until transferred to the Translational 127 Pharmacokinetics Research Laboratory, Obafemi Awolowo University, Ile-Ife using Arctic Express® Dry 128 Shipper (Thermo Scientific, Waltham, MA, USA) where they were stored at -80 °C until analysis.

#### 129 **Pharmacogenetic analysis and drug quantification**

130 Two CYP2B6 SNPs (CYP2B6 516G > T and CYP2B6 983 T > C) known to be associated with efavirenz plasma 131 exposure were included in this analysis. Genomic DNA was extracted from DBS using the QIAamp DNA 132 Blood Mini Kit (Qiagen, Germantown, USA ) and quantified using Nanodrop® spectrophotometer (Thermo 133 Fisher Scientific Inc., Wilmington, DE, USA) and stored at -70°C. Genotyping was performed by real-time 134 PCR based allelic discrimination using TaqMan<sup>®</sup> SNP genotyping assays for CYP2B6 516G>T (rs3745274 with 135 product ID C 7817765 60) and CYP2B6 983T>C (rs28399499 with product ID C 60732328 20) on a DNA 136 Engine Chromo4 system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The three-step PCR protocol included a 15-minute denaturation step at 95°C, 50 cycles of amplification at 95°C for 15 s each, and a 1-137 138 minute annealing step at 60°C. Opticon Monitor<sup>®</sup> version 3.1 (Bio-Rad Laboratories, Inc., Hercules, CA, USA) 139 enabled genotype calls based on allelic discrimination plots.

Determination of efavirenz concentration in CVF, plasma and DBS samples was conducted on a TSQ Quantum Access LC-MS/MS system (Thermo Fisher Scientific Inc., Hemel Hempstead, Hertfordshire, UK) at the Bioanalytical Laboratory, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria using previously reported methods [24,23]. To estimate plasma efavirenz concentration from DBS concentration,

7

the equation originally reported by Eyles et al ([25]) which accounts for the effect of fraction unbound toplasma proteins and haematocrit was used.

#### 146 Statistical analysis

147 Compliance with Hardy–Weinberg Equilibrium was tested as previously described. Efavirenz plasma and 148 CVF concentration dataset were subjected to Kolmogorov-Smirnov normality test prior to statistical 149 analysis. Spearman correlation was performed to test the relationship between continuous variables. 150 Variables associated with efavirenz concentration in plasma and CVF were determined using the univariate 151 linear regression analysis. Variables that showed significant association with efavirenz plasma and CVF 152 concentration in the univariate linear regression analysis were included in a multivariate stepwise linear 153 regression analysis. Differences in efavirenz plasma and CVF concentrations and pharmacokinetic 154 parameters between patient groups were investigated using 1-way analysis of variance (ANOVA) and 155 Mann–Whitney U test All these analyses were performed using IBM SPSS Statistics version 29.0.1.0 (171) 156 (IBM, Armonk, New York) and GraphPad Prism 10 (GraphPad Software, Inc., La Jolla, California).

#### 157 PResults

#### 158 Study participants

159 A total of 147 pregnant women contributed sparse pharmacokinetic samples in stage 1 at a mean (SD) 160 gestational age of 34.5 weeks (3.12), age 28.9 years (4.9) and body weight 64.3 kg (11.9). Median (range) 161 duration on therapy prior to enrolment into the preliminary phase of the study was 40.9 months (0.03 -162 149). Twelve pregnant women aged 28.9 years (4.9) old with body weight 65.7 kg (7.00) participated in the 163 intensive pharmacokinetic sampling of stage 2 at gestational age of 26.0 weeks (6.70). Postpartum 164 intensive pharmacokinetic sampling was conducted in 12 women aged 32.9 years (5.1) at 37.1 weeks (4.1) 165 after delivery. Total duration on ART prior to enrolment for stage 2 was 41.2 weeks (36.7) during pregnancy 166 and 55.8 weeks (27.3) for postpartum women. All study participants received efavirenz (600 mg), 167 lamivudine (300 mg) and tenofovir disoproxil fumarate (300 mg) fixed dose combination ART.

A total of 169 sparse samples (88 CVF, 81 plasma, and 73 paired samples at third trimester), 168 intensive CVF samples (84 samples each from the 12 pregnant and 12 postpartum women), and 98 DBS (48 samples each from 7 pregnant and 7 postpartum women) were available for analysis. The *CYP2B6* 516G>T SNP was in Hardy-Weinberg equilibrium within the study population.

8

#### 173 Are CYP2B6 516G>T and 983 T>C associated with efavirenz CVF concentration?

In stage 1, 88 sparse CVF and 81 plasma samples were obtained from a total of 92 participants during pregnancy (73 paired samples) to assess possible association between efavirenz concentration and *CYP2B6* polymorphisms (516G>T and 983 T>C). CVF and plasma samples were collected 14.45 h (1.30-17.02) after the last dose. The median (IQR) CVF and plasma efavirenz concentrations were 788 ng/mL (502-1542) and 1487 ng/mL (1041-2363), respectively. There was significant correlation in efavirenz CVF and plasma concentration at 90% confidence interval (p= 1.32 x 10<sup>-6</sup>, Pearson's r = 0.51 (0.37-0.66). The average CVFto-plasma ratio computed from the 73 paired sparse samples was 0.55.

The result indicates that only *CYP2B6 516G>T* is independently associated with efavirenz CVF and plasma concentration during pregnancy. The unstandardized regression coefficient ( $\beta$ )(90% confidence internal, *p*value) for this association is 997 ng/mL (598-1357, *p* = 5.7 x 10<sup>-5</sup>) and 1400 ng/mL (1051-1748, *p* = 5.7 x 10<sup>-9</sup>), respectively. Notably, *CYP2B6 516G>T* alone accounted for 20 % (adjusted R square = 0.20) and 40 % (adjusted R square = 0.40) of the observed differences in the efavirenz CVF and plasma concentrations during pregnancy, respectively. The association between *CYP2B6 516G>T* and efavirenz CVF as well as plasma concentration is presented in Figure 1.

No significant association was observed between efavirenz CVF concentration and *CYP2B6 983T>C* (p = 0.573), age (p = 0.134), body weight (p = 0.716), body mass index (p = 0.873), and time after dose (p = 0.729). Similarly, *CYP2B6 983T>C*, age, body weight, body mass index, and time after dose were not significantly associated with efavirenz plasma concentration.

Upon stratification based on *CYP2B6 516G>T*, we observed significant differences (p < 0.0001) in efavirenz median (IQR) CVF concentrations: GG (n=28), 559 ng/mL (342-874); GT (n= 45), 791 ng/mL (630-1475); TT (n=15), 3310 ng/mL (1332-4718). Similarly, plasma concentrations varied based on *CYP2B6 516G>T* (p < 0.0001): GG (n= 21), 1085 ng/mL (888-1305); GT (n= 48), 1495 ng/mL (1095-1983); TT (n=13), 4164 ng/mL

9

(2698-5903). Only *CYP2B6 516G>T*, was used to stratify study participants invited for the intensive
pharmacokinetic phase.

#### 198 What is the combined influence of pregnancy and genetics on efavirenz CVF exposure?

199 In the second stage, 12 pregnancy women (6GG and 6GT) and 12 postpartum women (4GG, 5GT and 3TT) 200 were invited for intensive pharmacokinetic sampling. Efavirenz concentration-time profile during 201 pregnancy and postpartum in the combine population and in CYP2B6 516GG and CYP2B6 516GT groups are 202 presented in Figure 2A. The corresponding pharmacokinetic parameters are presented in Table 2. In 203 pooled analysis, we observed a 87.7% increase (p-value at 90% confidence interval = 0.072) in the median 204 clearance, 46.4 % decrease in AUC<sub>0-24h</sub> (p = 0.042), 36.3% decrease in C<sub>max</sub> (p = 0.069), and 45.6 % decrease 205 in  $C_{min}$  (p = 0.085). However, upon stratification based on CYP2B6 516G>T, efavirenz median clearance 206 increased by 57.9% during pregnancy compared with postpartum control (p = 0.232) in patients with the 207 CYP2B6 516GT genotype. The AUC<sub>0-24h</sub>,  $C_{max}$  and  $C_{min}$  reduced by 33.8% ((p=0.182), 8.54% (0.175) and 208 59.9% (0.171) during pregnancy, with values of 20671 ng.h/ml (15993-28711), 1551 ng/ml (1087-2086) and 209 330 ng/ml (251-442), respectively, compared with 31229 ng.h/ml (27660-41873), 1695 ng/ml (1540-3003) and 814 ng/ml (486-981) during postpartum. In the contrary, efavirenz CVF exposure was marginally 210 increased during pregnancy in patients with the CYP2B6 516GG genotype (Table 2). We could not compare 211 212 between the pharmacokinetic parameters of patients with the CYP2B6 516TT genotype in the pregnancy 213 and postpartum cohorts because there were no patients with the CYP2B6 516TT genotype in the pregnancy 214 cohort.

### 215 Efavirenz CVF and Plasma pharmacokinetics during pregnancy and postpartum

Efavirenz pharmacokinetic parameters differed significantly in CVF and plasma. Median (IQR) pharmacokinetic parameters in CVF (n=12) versus plasma (n=7) were  $AUC_{0-24}$ , 16465 ng.h/mL (9356-30417) versus 48983 ng.h/mL (41414-54311);  $C_{max}$ , 1031 ng/mL (585-1771) versus 5080 ng/mL (4535-5364); and

10

C<sub>min</sub>, 243 ng/mL (168-402) versus 844 ng/mL (534-1109) during pregnancy, and 30715 ng.h/mL (10980-43714) versus 67339 ng.h/mL (57492-106868); C<sub>max</sub>, 1618 ng/mL (675-2695) versus 5174 ng/mL (4643-6988); and C<sub>min</sub>, 447 ng/mL (159-974) versus 2192 ng/mL (1637-6485) in postpartum women. CVF-toplasma C<sub>max</sub> and AUC<sub>0-24</sub> ratios were 0.20 and 0.34 during pregnancy, and 0.31 and 0.46 during postpartum. Time to reach efavirenz maximum plasma versus CVF concentration were 2.00 h (2.00-4.00) vs 8.00 h (7.00 - 9.00) and 2.00 h (2.00-2.00) vs 8.00 h (8.00 – 12.0) in pregnant and postpartum women, respectively.

225 Discussion

226 The female genital tract (FGT) is an important sanctuary site where a significant proportion of MTCT occur 227 during delivery. Strategies to reduce HIV transmission rates focuses on reducing the amount of virus in the 228 FGT with antiretroviral therapy [26]. A good knowledge of the factors that affect the disposition of 229 antiretroviral drug into the FGT of HIV-infected pregnant women can potentially aid accurate assessment of 230 antiretroviral-exposure relationships and improve maternal-infant survival outcomes. The impact of 231 pregnancy and host genetics on the disposition of ART into the FGT has not been well studied. In this study, 232 we performed a clinical pharmacokinetic study to describe efavirenz FGT disposition in genetically defined 233 pregnant and postpartum women.

234 Our findings indicates that efavirenz distributes rapidly into the cervicovaginal fluid (CVF) of pregnant and 235 postpartum women after oral dosing. Although efavirenz minimum effective concentration in the FGT has 236 not been established, concentrations exceeding the efavirenz PBIC<sub>90% (</sub>126 ng/ml) for wild-type HIV-1 237 measured within 30 minutes post-drug administration in 83% of pregnant and postpartum women studied 238 may suggest that efavirenz administration at 600 mg may be sufficient to reduce HIV MTCT at the time of 239 delivery. Comparatively, we observed that efavirenz CVF disposition is positively correlated with plasma 240 exposure (Pearson's r = 0.76 (0.65 – 0.85),  $R^2$  = 0.58, P-value < 0.0001), with CVS:plasma efavirenz AUC 0.24h 241 observed to be 0.34 and 0.46 in the pregnant and postpartum women who contributed the intensive 242 pharmacokinetic samples. Some other studies have also reported good penetration of antiretroviral drugs

11

into the FGT. For example, CVF-plasma concentration ratios of 2.3 (1.4 – 4.1), 3.2 (1.2 – 8.5) and 5.2 (1.2 –
22.6) have been reported for raltegravir [27], lamivudine [2] and tenofovir [2], respectively.

245 Factors such as molecular weight and protein binding can determine the extent of drug distribution into the 246 FGT. Efavirenz is a low molecular drug and it is expected to be able to penetrate the female genital tissues 247 and fluid. Drugs penetration into the female genital tissues appear to be influence by its protein binding 248 ability. Highly protein bound drugs generally tends to have more capacity to penetrate the FGT compared 249 to poorly bound drugs [28]. Efavirenz protein binding in the CVF was not determined in this study. However, 250 based on previous reports, the concentrations of drug binding proteins (mainly albumin and alpha 1- acid 251 glycoproteins) has been previously reported to be approximately 1% of what is obtained in blood plasma 252 [29]. Also, maraviroc CVF protein binding have been reported to be 10% of plasma protein binding [30]. 253 Based on this information, it can be assumed that efavirenz CVF protein binding is limited hence the high 254 concentration of the drug in the CVF.

255 Our results indicate a 46% reduction in efavirenz CVF AUC<sub>0-24 h</sub> during pregnancy relative to postpartum 256 values. Both efavirenz CVF C<sub>min</sub> and C<sub>max</sub> during pregnancy were substantially lower than postpartum by 257 45.6% and 36.3% respectively. Efavirenz clearance from the CVF was markedly increased (87.6% increment) 258 during pregnancy compared to postpartum control. Reduced antiretroviral CVF exposure during pregnancy 259 may be associated with sub-optimal suppression of viral replication in the FGT and increased risk of MTCT 260 of HIV, particularly among HIV-positive pregnant women who were diagnosed of HIV and commence ART in 261 late pregnancy. The onset of pregnancy is well known to be associated with maternal physiological changes 262 [31]. These changes could alter drug disposition and may explain the reduction in the CVF exposure of 263 efavirenz observed in this study.

Efavirenz is predominantly metabolized by CYP2B6 [32] and the *CYP2B6* 516G>T genotype has been shown to reduce the rate of efavirenz biotransformation to its major metabolite, efavirenz 8-hydroxylation [33].

12

266 We found that on CYP2B6 516G>T genotype was strongly associated with efavirenz CVF disposition in 267 pregnant and postpartum women. Efavirenz concentration in the CVF varies depending on CYP2B6 516GT 268 genotypes during pregnancy and postpartum, with the lowest CVF exposure measured in subjects stratified 269 as CYP2B6 516GG genotype. The overall CVF exposure of efavirenz in pregnant women classified as CYP2B6 270 516GG genotype was lower by 43.9% compared to those classified as CYP2B6 516GT genotype. On the 271 other hand, the overall efavirenz CVF exposure in postpartum women classified CYP2B6 516TT genotype 272 exceeded those classified as CYP2B6 516GG and CYP2B6 516GT by 273% and 27.0%, respectively. This 273 findings suggests that CYP2B6 Single Nucleotide Polymorphisms (SNPs) play a role in efavirenz CVF 274 disposition

275 Efavirenz CVF C<sub>min</sub> was above the reported value of 126 ng/mL for the wild type HIV-1 in 75% of postpartum 276 women with the CYP2B6 516GG genotype, compared to 100% in pregnant women with the same genotype. 277 The genotype-dependent changes in the efavirenz CVS exposure observed in this study may therefore be 278 explained by possible genotype-dependent differences in efavirenz autoinduction in the human female 279 genital tract. Unfortunately, the expression of CYP2B6 isoenzyme and its potential autoinduction in the 280 human female genital tract or any other genetic factors was not directly assessed in this study. This is 281 considered one of the limitations of this study and further studies in this area are recommended. Our 282 results supports CYP2B6 516G>T-guided dosing of efavirenz in pregnant women.

The findings from this study need to be interpreted with caution and in the context of the limitation associated with the conduct of this study. Firstly, the women who contributed the intensive pharmacokinetic samples during pregnancy were different from cohorts who contributed the postpartum samples. Since the cohorts of the pregnant women were not used as their own postpartum control, there may be some bias in the interpretation of the effect of pregnancy and host genetics on efavirenz CVF exposure.

- 289 In conclusion, the study established pregnancy and CYP2B6 SNPs play an important role in efavirenz
- 290 disposition into the female genitalia.

## 291 Acknowledgements

- 292 The authors acknowledge bioanalytical facility support from the Obafemi Awolowo University Bioanalytical
- 293 Laboratory, Nigeria and the University of Liverpool, United Kingdom.

- - <del>-</del>

14

## 313 Figure Legends

- Figure 1: Association of pooled *CYP2B6 c.* 516/985 with EFV CVS concentrations during pregnancy in the
- preliminary phase. *P* values on figures are for Mann-Whitney U / Kruskal Wallis test.
- Figure 2: Efavirenz CVF concentration-time profiles (mean, SEM) during pregnancy and postpartum (A).
- 317 Comparison shows decreased exposure during pregnancy (n = 12) compared with postpartum (n = 12).
- 318 Upon stratification of patients based on CYP2B6 516G>T status showed decreased exposure during
- pregnancy (n = 6) compared with postpartum (n = 4) in patients with the GG genotype(B). Similarly,
- 320 efavirenz exposure decreased in pregnant women (n=6) compared to postpartum women (n=5) with the GT
- 321 genotype (C). None of the pregnant women recruited into the intensive phase of this study had the TT
- 322 genotype. Median (range) C<sub>min</sub>, C<sub>max</sub>, and AUC<sub>0-24</sub> of postpartum women (n=3) with the TT genotype status
- 323 were 972 (587-2383), 2587 (1633-4365) and 39673 (25147-64938), respectively.

#### 324 References

- 1 Devanathan AS, Cottrell ML. Pharmacology of HIV Cure: Site of Action. *Clin. Pharmacol. Ther.* 109(4),
  841–855 (2021).
- 327 2 Kwara A, DeLong A, Rezk N et al. Antiretroviral Drug Concentrations and HIV RNA in the Genital Tract of
- HIV-Infected Women Receiving Long-Term Highly Active Antiretroviral Therapy. Clin. Infect. Dis. 46(5),

329 719–725 (2008).

- 3 Adams JL, Patterson KB, Prince HM *et al.* Single and Multiple Dose Pharmacokinetics of Dolutegravir in
   the Genital Tract of HIV Negative Women. *Antivir. Ther.* 18(8), 1005–1013 (2013).
- 4 Neely M, Louie S, Xu J et al. Simultaneous plasma and genital pharmacokinetics and pharmacodynamics
- of atazanavir and efavirenz in HIV-infected women starting therapy. *J. Clin. Pharmacol.* 55(7), 798–808
  (2015).
- Gianella S, Marconi VC, Berzins B *et al.* Genital HIV-1 Shedding with Dolutegravir (DTG) plus Lamivudine
  (3TC) Dual Therapy. *J. Acquir. Immune Defic. Syndr. 1999* 79(5), e112–e114 (2018).
- 337 6 Olagunju A, Nwogu J, Eniayewu O et al. Validation and clinical application of a method to quantify
- efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass
- 339 spectrometry. *Wellcome Open Res.* 6, 246 (2022).
- 7 Olagunju A, Bolaji O, Amara A *et al.* Pharmacogenetics of pregnancy-induced changes in efavirenz
   pharmacokinetics. *Clin. Pharmacol. Ther.* 97(3), 298–306 (2015).
- 342 8 Olagunju A, Bolaji O, Neary M, Back D, Khoo S, Owen A. Pregnancy affects nevirapine pharmacokinetics:
- evidence from a CYP2B6 genotype-guided observational study. *Pharmacogenet. Genomics* 26(8), 381–
  389 (2016).
- Mulligan N, Best BM, Wang J *et al.* Dolutegravir pharmacokinetics in pregnant and postpartum women
  living with HIV. *AIDS Lond. Engl.* 32(6), 729–737 (2018).

- 347 10 Bukkems VE, Necsoi C, Hidalgo Tenorio C et al. Tenofovir Alafenamide Plasma Concentrations Are
- 348 Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA
- 349 Network. *Clin. Infect. Dis.* 75(4), 623–629 (2022).
- 350 11 Saracino A, Di Stefano M, Vimercati A et al. Cervicovaginal HIV-1 Shedding in Pregnant Women near
- 351 Delivery. Antivir. Ther. 6(1), 79–81 (2001).
- 352 12 Frenkel LM, Morrison RL, Fuller TL et al. Brief Report: Vaginal Viral Shedding With Undetectable Plasma
- HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical
- 354 Trial. J. Acquir. Immune Defic. Syndr. 1999 88(4), 361–365 (2021).
- 13 Keita A, Rigaill J, Pillet S et al. Evidence of HIV-1 Genital Shedding after One Year of Antiretroviral
- Therapy in Females Recently Diagnosed in Bamako, Mali. *Microorganisms* 9(10), 2164 (2021).
- 357 14 Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-
- 358 child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland,
- 359 2000–2006. *AIDS* 22(8), 973 (2008).
- 15 Baeten JM, Kahle E, Lingappa JR *et al.* Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1
   Transmission. *Sci. Transl. Med.* 3(77), 77ra29-77ra29 (2011).
- 16 King CC, Ellington SR, Davis NL *et al.* Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in
   Women on Antiretroviral Therapy. *J. Infect. Dis.* 216(12), 1534–1540 (2017).
- 364 17 UNAIDS. "global hiv & aids statistics fact sheet 2023 Google Search" (2023).
- 365 https://www.google.com/search?q=global+hiv+%26+aids+statistics+%E2%80%94+fact+sheet+2023&rlz=
- 366 1C1JZAP\_enNG1061NG1061&oq=Global+HIV+%26+AIDS+statistics+%E2%80%94+Fact+sheet+2023&aqs
- 367 =chrome.0.0i512.3097j0j4&sourceid=chrome&ie=UTF-8.
- 368 18 Kourtis AP, Lee FK, Abrams EJ, Jamieson DJ, Bulterys M. Mother-to-child transmission of HIV-1: timing
- and implications for prevention. *Lancet Infect. Dis.* 6(11), 726–732 (2006).

370	19 Duri K, Munjoma PT, Mazhandu AJ et al. Predictors and Timing to Viral Suppression in HIV-Infected
371	Pregnant Women in the University of Zimbabwe Birth Cohort Study During the Era of Lifelong
372	Antiretroviral Therapy (Option B+ Treatment Strategy). Front. Virol. 2 (2022).
373	20 Cottrell ML, Prince HMA, Allmon A et al. Cervicovaginal and Rectal Fluid as a Surrogate Marker of
374	Antiretroviral Tissue Concentration: Implications for Clinical Trial Design. J. Acquir. Immune Defic. Syndr.
375	<i>1999</i> 72(5), 498–506 (2016).
376	21 Bennetto-Hood C, Johnson VA, King JR, Hoesley CJ, Acosta EP. Novel Methodology for Antiretroviral
377	Quantitation in the Female Genital Tract. <i>HIV Clin. Trials</i> 10(3), 193–199 (2009).
378	22 Olagunju A, Anweh D, Okafor O et al. Viral and antiretroviral dynamics in HIV mother-to-child
379	transmission fluids (VADICT)–Protocol and data analysis plan for a cohort study. Wellcome Open Res.
380	4(34), 34 (2019).
381	23 Olagunju A, Nwogu J, Eniayewu O et al. Validation and clinical application of a method to quantify
382	efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass
383	spectrometry. Wellcome Open Res. 6, 246–246 (2021).
384	24 Amara AB, Else LJ, Tjia J et al. A validated method for quantification of efavirenz in dried blood spots
385	using high-performance liquid chromatography-mass spectrometry. Ther. Drug Monit. 37(2), 220–228
386	(2015).
387	25 Eyles D, Anderson C, Ko P <i>et al.</i> A sensitive LC/MS/MS assay of 250H vitamin D3 and 250H vitamin D2 in
388	dried blood spots. Clin. Chim. Acta Int. J. Clin. Chem. 403(1–2), 145–151 (2009).
389	26 Cu-Uvin S, Caliendo AM, Reinert S et al. Effect of highly active antiretroviral therapy on cervicovaginal
390	HIV-1 RNA. AIDS Lond. Engl. 14(4), 415–421 (2000).
391	27 Clavel C, Peytavin G, Tubiana R et al. Raltegravir Concentrations in the Genital Tract of HIV-1-Infected
392	Women Treated with a Raltegravir-Containing Regimen (DIVA 01 Study). Antimicrob. Agents Chemother.
393	55(6), 3018–3021 (2011).

18

- 28 Dumond JB, Yeh RF, Patterson KB *et al.* Antiretroviral drug exposure in the female genital tract:
   implications for oral pre- and post-exposure prophylaxis. *AIDS Lond. Engl.* 21(14), 1899–1907 (2007).
- 396 29 Salas Herrera IG, Pearson RM, Turner P. Quantitation of albumin and alpha-1-acid glycoprotein in human
- 397 cervical mucus. *Hum. Exp. Toxicol.* 10(2), 137–139 (1991).
- 398 30 Dumond JB, Patterson KB, Pecha AL *et al.* Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal
- Tissue of HIV-Negative Women. J. Acquir. Immune Defic. Syndr. 1999 51(5), 546–553 (2009).
- 400 31 Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. *Clin.*
- 401 *Pharmacokinet.* 44(10), 989–1008 (2005).
- 402 32 Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the
- 403 main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and
- 404 utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306(1),
- 405 287–300 (2003).
- 406 33 Olagunju A, Bolaji O, Amara A *et al.* Pharmacogenetics of pregnancy-induced changes in efavirenz 407 pharmacokinetics. *Clin. Pharmacol. Ther.* 97(3), 298–306 (2015).

19




Figure 1: Association of pooled *CYP2B6* 516G>T with EFV Cervicovaginal fluid (CVF) concentrations during pregnancy. *P* values on figures are for Mann-Whitney U / Kruskal Wallis test. GG; patients with two normal function *CYP2B6* allele, GT; patients with one normal and one decreased function *CYP2B6* allele, TT; patients with two decreased function *CYP2B6* alleles

20

# **Table 1:** Univariate linear regression analysis of factors influencing efavirenz CVF disposition in pregnant

415 women.

Predictors	β (ng/mL) [90% CI]	<i>p</i> -values
Age (years)	54.9 (-5.41 – 115)	0.134
Body weight (kg)	-4.31 (-24.0 – 15.4)	0.716
Time post-dose (h)	-42.3 (-246 – 161)	0.729
BMI (kg/m <sup>2</sup> )	4.64 (-43.6 - 52.9)	0.873
CYP2B6 516G>T	997.0 (598 – 1357)	5.7 x 10 <sup>-5</sup>
CYP2B6 983T>C	-302 (-1189 – 586)	0.573
CYP2B6 516/983 G>T	916 (541 – 1290)	1.2 x 10 <sup>-3</sup>
16		
17		
18		
19		
20		
21		
122		
23		
24		
25		
26		
27		
28		
29		
130		
31		

435 Results are presented in median (Interquartile range, IQR).

PK parameters	Combined (n=12)	<i>CYP2B6</i> 516GG (n = 6)	<i>CYP2B6</i> 516GT (n = 6)	
Pregnancy				
$C_{min}$ (µg/mL)	243 (168 - 402)	169 (164 – 242)	330 (250 – 440)	
$C_{max}$ (µg/mL)	1031 (595 –1771)	664(596 – 1069)	1550 (1090 – 2090)	
$AUC_{0-24h}$ (µg.h/mL)	16465 (9356 – 30417)	11577 (7507 – 13284)	20671 (15993 – 28712)	
CL/F (L/h)	36.6 (19.7 – 65.1)	52.0 (42.0 – 79.9)	30 (21 – 37.6)	
T <sub>max</sub> (h)	8.00 (7.00 - 9.00)	8.00 (4.00 – 12.0)	8.00 (8.00 – 8.00)	
Postpartum	Combined (n=12)	<i>CYP2B6</i> 516GG (n = 4)	<i>CYP2B6</i> 516GT (n = 5)	<i>CYP2B6</i> 516TT (n = 3)
C <sub>min</sub> (ng/mL)	447 (159 – 974)	151 (116 – 225)	814 (496 – 981)	972 (587 – 2383)
C <sub>max</sub> (ng/mL)	1618 (675 – 2695)	636 (583 – 1107)	1695(1540 - 3003)	2587 (1633 – 4365)
AUC <sub>0-24h</sub> (ng.h/mL)	30715 (10980 – 43714)	10630(9848 - 15875)	31229 (27660 – 41873)	39673 (25147 – 64938)

CL/F (L/h)	19.5 (13.8 – 54.7)	57.0 (46.0 - 61.1)	19.0 (14.0 – 22.0)	15 (10.9 – 35.8)
T <sub>max</sub> (h)	8.0 (8.0 - 8.0)	8.0 (7.0 - 8.0)	8.0 (8.0 - 8.0)	8.0 (8.0 - 8.0)




Figure 2: Efavirenz CVF concentration-time profiles (mean, SEM) during pregnancy and postpartum